Atrys 1H FY26 EBITDA climbs 21.3% to EUR 9.3 million; revenue rises 9.4% to EUR 77.7 million
Reuters2026/09/10 06:24- Atrys posted H1 2026 revenue of EUR 77.7 million, up 9.4% from a year earlier; EBITDA rose 21.3% to EUR 9.3 million.
- Operating cash flow climbed to EUR 7.2 million, up 191.5%, reflecting higher EBITDA and streamlined investment of EUR 2.1 million.
- Net financial debt fell 79.2% to EUR 35.4 million after the January ASPY sale; financial expenses dropped by EUR 4.4 million.
- Oncology revenue rose 22.5% to EUR 37.1 million; Nuclear Medicine EBITDA more than doubled on strong performance in Portugal.
- Guidance reaffirmed for 2026: revenue EUR 156.5 million, up 11%; reported EBITDA EUR 20.5 million, up 40%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
How will the 110 trillion KRW AI dividend be distributed? Seoul-based hedge fund pressures Samsung to immediately buy back and cancel preferred shares
A South Korean hedge fund is pressuring Samsung to buy back and cancel its preferred shares, planning to use 73 trillion won of a 110 trillion won return plan for the repurchase, aiming to eliminate a discount of over 25%.
Extreme level of 8,500 emerges! Two top strategists raise S&P 500 target as strong earnings become key support
Despite facing a surge in US Treasury yields surpassing 5% and a slowdown in the AI sector, Wall Street institutions continue to raise their S&P 500 target prices, with the most bullish forecasts reaching up to 8,500 points.
BIG Impact invests in autoimmune diagnostics and drug discovery startup AOI Biosciences
LG Electronics Gains a Bull on Likely 3Q Earnings Beat -- Market Talk
Crypto prices
More
